Medicine
Bryhali 0.01% lotion
Bryhali 0.01% lotion is a prescription medicine containing Halobetasol propionate for topical use, marketed by Bausch Health, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing. Store at 20° to 25°C (68° to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Halobetasol propionate
- Brand
- Bryhali
- Strength
- 0.01%
- Dosage form
- Lotion
- Route
- Topical
- Packs
- 1 tube
- Marketing authorisation holder
- Bausch Health
- Manufacturer
- Bausch Health
- Origin register
- US FDA, United States
- Storage
- Protect from freezing. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D07AC21 Halobetasol propionate
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 November 2018
- Identifiers
- RxCUI 2101710, 2101715DailyMed set ID d4bbb66a-3f9d-4091-b1b0-1cbc908432d3NDC 0187-0002Application NDA209355
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 tube in 1 carton / 100 g in 1 tube | 0187-0002-01 | Bausch Health | 6 November 2018 |
| 1 tube in 1 carton / 60 g in 1 tube | 0187-0002-60 | Bausch Health | 6 November 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 17 December 1990 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Halobetasol propionate
Clinical summary
Halobetasol propionate is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. It is available as ointment, cream and lotion for topical use. MedsAcross supplies Halobetasol propionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Halobetasol propionateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Halobetasol Propionate prescribing information (Coral Way Pharma) · U.S. National Library of Medicine, DailyMed
Need Bryhali 0.01% lotion for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.